Dianthus removes the complexity of binding interaction measurements for drug discovery screening. Find hits for any target type in any buffer or bioliquid, measure the tightest interactions down to picomolar Kds, all by consuming the smallest amount of your target and library compounds. There’s no fluidics which means no regular maintenance and no downtime. With Dianthus, get the fastest time to meaningful results with no immobilization required. Learn more here: nanotempertech.com/dianthus Have a question?: nanotempertech.com/contact-specialist/
Have a question about Dianthus?
Contact SpecialistSee more related content
59:35Bifunctional degrader molecules (also known as PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases. The formation of a ternary complex between PROTAC, ligase, and the protein of inte
Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology
Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make it a priority to have an adequate lineup of instruments for their screening campaigns. They decide on what...
Follow these 7 tips when pipetting small volumes to get consistent assay results
If you’ve ever had to pipette really small volumes, such as what is required in 384-well plates, you’re definitely familiar with the frustrations that come along with it. The concentration alone...
6 protein degradation conferences in 2021 you can’t afford to miss
Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation (TPD). Many transcription factors, scaffold proteins,...
3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs
A caveat to a successful pharmaceutical industry in which many effective drugs have already been discovered is the notion that the high hanging fruits left unpicked come in the form of challenging...
The NanoTemper Story – Chapter 5: The Dianthus
Almost as soon as the Monolith launched, the handful of people that made up NanoTemper in those early days huddled around, brainstorming how to translate the technology into a well-based assay....
High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale
17:10There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t
17:07A big hurdle in small molecule drug discovery screening is confidently identifying positive hits in a timely manner. Screening fragment libraries is challenging with current methodologies that are eit
3 big takeaways from SLAS on the future of automation and screening
5,200 researchers, representing all of life sciences, gathered in San Diego in late January to discuss the latest in automation and screening solutions. Improvements in automation and screening...
16:04Neurodegenerative diseases like Alzheimer’s or Parkinson’s Disease affect millions of people worldwide. Although current treatments may help relieve some of the physical or mental symptoms, there is s
When aptamers are the better choice over mAbs
Monoclonal antibodies (mAbs) have become the molecule of choice when highly specific molecular recognition is needed for a variety of applications including disease diagnosis and therapy....
6 ingredients for a successful fragment library
Fragment-based drug discovery (FBDD) has become a major strategy to derive novel lead candidates in drug discovery. The principle of FBDD is to start with very small molecular fragments which may...